Manuel Bardiès obtained his Doctorate on radiopharmaceutical dosimetry (with distinction) from Paul Sabatier University (Toulouse III) in November 15, 1991. He has been developing his research in radiopharmaceutical dosimetry within INSERM since 1991, in Nantes then in Toulouse.
Under his responsibility:
- 10 PhD dissertations have been defended since 2000,
- 2 PhD projects are ongoing
- 2 PhD projects is ongoing under the form of a co-supervision
Master training: about 30 Master student projects since 1995
Other training (Engineering students): about 20 students since 1996
Several academic or industrial projects have been funded and involved recruiting Post-Doctoral scientists.
Manuel Bardiès has authored or participated to more than 60 articles referenced in MedLine.
The team led by Manuel Bardiès in Toulouse is primarily involved in radiopharmaceutical dosimetry, at various scales (cell, tissue, organ). This requires the ability to assess radiopharmaceutical pharmacokinetics in vivo, through quantitative SPECT or PET small-animal imaging. An important part of research activity is related to Monte-Carlo modeling of radiation transport through biologic structures of interest, in order to give account of energy deposition within tumour targets – or conversely critical non-tumour tissues/organs. The objective is to improve molecular radiotherapy by allowing patient-specific treatments (personalized medicine).
Memberships
American Association of Physicists in Medicine (AAPM)
Member of task-group No. 7/Consultants on Radionuclide Therapy de l'AAPM (since 2000)
European Association of Nuclear Medicine (EANM)
Member of the EANM Dosimetry Committee from 2001
Chairman of EANM Dosimetry Committee (2009-2011)
Senior adviser of EANM Dosimetry Committee (2012-2013)
European Federation of Organisations for Medical Physics (EFOMP)
Vice-Chairman of Scientific Committee (2013)
Chairman of Scientific Committee from de 2014
